Jerrold L Boxerman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/465405/publications.pdf

Version: 2024-02-01

36 papers 4,179 citations

304743

22

h-index

395702 33 g-index

37 all docs

37 docs citations

37 times ranked

4147 citing authors

#	Article	IF	CITATIONS
1	Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors. Neuro-Oncology, 2022, 24, 1219-1229.	1.2	9
2	Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials. Neuro-Oncology, 2021, 23, 189-198.	1.2	11
3	Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial. Neuro-Oncology, 2021, 23, 314-323.	1.2	18
4	Robust breast cancer detection in mammography and digital breast tomosynthesis using an annotation-efficient deep learning approach. Nature Medicine, 2021, 27, 244-249.	30.7	187
5	Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro-Oncology, 2021, 23, 1056-1071.	1.2	68
6	The relationship between cerebral and retinal microbleeds in cerebral amyloid angiopathy (CAA): A pilot study. Journal of the Neurological Sciences, 2021, 423, 117383.	0.6	6
7	Encephalopathy at admission predicts adverse outcomes in patients with SARSâ€CoVâ€2 infection. CNS Neuroscience and Therapeutics, 2021, 27, 1127-1135.	3.9	3
8	Septopreoptic Holoprosencephaly in an Adolescent Presenting with Hypodipsia and Hypernatremia. Journal of Pediatrics, 2021, , .	1.8	0
9	Detecting Large Vessel Occlusion at Multiphase CT Angiography by Using a Deep Convolutional Neural Network. Radiology, 2020, 297, 640-649.	7.3	48
10	Bloodâ€brain barrier dysfunction and perioperative neurocognitive disorders: Cognitive Recovery after Elective Surgery (CREATES) study design and methods. Alzheimer's and Dementia, 2020, 16, e039363.	0.8	0
11	Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. Neuro-Oncology, 2020, 22, 1262-1275.	1.2	109
12	Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. Neuro-Oncology, 2020, 22, 757-772.	1.2	131
13	Interreader Variability of Dynamic Contrast-enhanced MRI of Recurrent Glioblastoma: The Multicenter ACRIN 6677/RTOG 0625 Study. Radiology, 2019, 290, 467-476.	7.3	15
14	Evaluating Multisite rCBV Consistency from DSC-MRI Imaging Protocols and Postprocessing Software Across the NCI Quantitative Imaging Network Sites Using a Digital Reference Object (DRO). Tomography, 2019, 5, 110-117.	1.8	25
15	Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686. Neuro-Oncology, 2018, 20, 1400-1410.	1.2	27
16	Myelin water fraction changes in febrile seizures. Clinical Neurology and Neurosurgery, 2018, 175, 61-67.	1.4	7
17	Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 228-234.	1.3	77
18	Toxoplasmosis versus lymphoma: Cerebral lesion characterization using DSC-MRI revisited. Clinical Neurology and Neurosurgery, 2017, 152, 84-89.	1.4	26

#	Article	IF	Citations
19	A Population-Based Digital Reference Object (DRO) for Optimizing Dynamic Susceptibility Contrast (DSC)-MRI Methods for Clinical Trials. Tomography, 2017, 3, 41-49.	1.8	30
20	Dynamic Susceptibility Contrast MR Imaging in Glioma. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 649-670.	1.1	43
21	Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)â€MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab. Journal of Magnetic Resonance Imaging, 2016, 44, 1229-1237.	3.4	27
22	Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma. Neuro-Oncology, 2016, 18, 467-478.	1.2	67
23	Response Assessment and Magnetic Resonance Imaging Issues for Clinical Trials Involving High-Grade Gliomas. Topics in Magnetic Resonance Imaging, 2015, 24, 127-136.	1.2	20
24	NIMG-25IMPROVED LEAKAGE CORRECTION FOR DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI ESTIMATES OF RELATIVE CEREBRAL BLOOD VOLUME (rCBV) IN HIGH-GRADE GLIOMAS BY ACCOUNTING FOR BIDIRECTIONAL CONTRAST AGENT EXCHANGE. Neuro-Oncology, 2015, 17, v159.1-v159.	1.2	O
25	Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. Neuro-Oncology, 2015, 17, 1148-1156.	1.2	108
26	Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment. Neuro-Oncology, 2015, 17, 1538-1539.	1.2	7
27	Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro-Oncology, 2015, 17, 1188-98.	1.2	346
28	Ipilimumab treatment associated pituitary hypophysitis: Clinical presentation and imaging diagnosis. Clinical Neurology and Neurosurgery, 2014, 125, 125-130.	1.4	55
29	An Efficient Computational Approach to Characterize DSC-MRI Signals Arising from Three-Dimensional Heterogeneous Tissue Structures. PLoS ONE, 2014, 9, e84764.	2.5	21
30	Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. Neuro-Oncology, 2013, 15, 945-954.	1.2	74
31	Preoperative MRI Evaluation of Pituitary Macroadenoma: Imaging Features Predictive of Successful Transsphenoidal Surgery. American Journal of Roentgenology, 2010, 195, 720-728.	2.2	91
32	Is Rolandic epilepsy associated with abnormal findings on cranial MRI?. Epilepsy Research, 2007, 75, 180-185.	1.6	40
33	The intravascular contribution to fmri signal change: monte carlo modeling and diffusion-weighted studiesin vivo. Magnetic Resonance in Medicine, 1995, 34, 4-10.	3.0	570
34	Mr contrast due to intravascular magnetic susceptibility perturbations. Magnetic Resonance in Medicine, 1995, 34, 555-566.	3.0	922
35	Microscopic susceptibility variation and transverse relaxation: Theory and experiment. Magnetic Resonance in Medicine, 1994, 31, 601-610.	3.0	663
36	Pitfalls in MR measurement of tissue blood flow with intravascular tracers: Which mean transit time?. Magnetic Resonance in Medicine, 1993, 29, 553-558.	3.0	327